Buscar
Neurosense Therapeutics Ltd
NRSNAñadir a la lista de seguimiento
0.723USD
+0.003+0.42%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
23.54MCap. mercado
PérdidaP/E TTM
Más Datos de Neurosense Therapeutics Ltd Compañía
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Información de Neurosense Therapeutics Ltd
Símbolo de cotizaciónNRSN
Nombre de la empresaNeurosense Therapeutics Ltd
Fecha de salida a bolsaDec 09, 2021
Director ejecutivoBen-Noon (Alon)
Número de empleados15
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 09
Dirección11 Hamenofim St.
CiudadHERZLIYA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal4672562
Teléfono97297996183
Sitio Webhttps://www.neurosense-tx.com/
Símbolo de cotizaciónNRSN
Fecha de salida a bolsaDec 09, 2021
Director ejecutivoBen-Noon (Alon)
Ejecutivos de Neurosense Therapeutics Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Neurosense Therapeutics Ltd?
Los cinco principales accionistas de Neurosense Therapeutics Ltd son: Mr. Alon Ben-Noon
¿Cuántas instituciones poseen acciones de Neurosense Therapeutics Ltd (NRSN)?
A fecha de 2026Q1, 33 instituciones poseen acciones de Neurosense Therapeutics Ltd, con un valor de mercado combinado de aproximadamente 367.79K, lo que representa el 1.04% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2009158.00.